Tom Lund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tom Lund has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Adam Pennycuick
UCL Respiratory, University College London, London, UK
14 shared publications - Ayse U. Akarca
Department of Cellular Pathology, University College London Hospitals, London, UK
14 shared publications - Claire Marceaux
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
14 shared publications - Deepak P. Chandrasekharan
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
14 shared publications - Fraser R. Millar
Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XR, UK
14 shared publications Jeremy George
14 shared publications
Latest Publications
- Open Access
A Digital Environment for Multi-modal Relational Management, Representation, and Analysis of Cancer Clinical Studies
Biologically rich clinical trials generate heterogeneous datasets whose relationships and clinical context must be preserved. Here we present the POETIC-AI environment, a trial-centric digital environment for integrating, analysing, and exploring multimodal data from POETIC, a randomised phase III trial of peri-operative aromatase inhibition in hormone receptor-positive breast cancer ( NCT02338310 ). We implemented a graph-based ontology linking patients, treatments, sampling timepoints, specimens, assays, images, spatial regions, and derived measurements; and designed code-based and graphical analytical workflows. Using proliferation as a test case, we reproduced POETIC’s established reduction in Ki67% and examined variation underlying sample-level measurements. In response-enriched cohorts, mean Ki67% decreased while relative variation among pathologist-assessed fields increased (paired Wilcoxon, P < 0.0001). Pathologist-assessed Ki67% correlated strongly with an 18-gene transcriptomic proliferation signature ( r = 0.834), and both decreased significantly during treatment (P < 0.0001). An annotation-free pixel-wise Ki67 H-score showed weaker correlations and a similar but non-significant reduction ( r = 0.327-0.472; P = 0.15), highlighting differences between tumour-focused and whole-section image quantification. Digital pathology and spatial molecular measurements remained linked to their source images and annotated tissue regions, enabling exploration within their morphological and spatial context using bespoke interactive applications. POETIC-AI demonstrates how the structure, provenance, and tissue context of evolving multimodal clinical-trial data can be preserved within a connected research environment, supporting reproducible analyses and the laying the groundwork for future development of biologically interpretable computational biomarkers.
Open AccessA Digital Environment for Multi-modal Relational Management, Representation, and Analysis of Cancer Clinical Studies
Biologically rich clinical trials generate heterogeneous datasets whose relationships and clinical context must be preserved. Here we present the POETIC-AI environment, a trial-centric digital environment for integrating, analysing, and exploring multimodal data from POETIC, a randomised phase III trial of peri-operative aromatase inhibition in hormone receptor-positive breast cancer ( NCT02338310 ). We implemented a graph-based ontology linking patients, treatments, sampling timepoints, specimens, assays, images, spatial regions, and derived measurements; and designed code-based and graphical analytical workflows. Using proliferation as a test case, we reproduced POETIC’s established reduction in Ki67% and examined variation underlying sample-level measurements. In response-enriched cohorts, mean Ki67% decreased while relative variation among pathologist-assessed fields increased (paired Wilcoxon, P < 0.0001). Pathologist-assessed Ki67% correlated strongly with an 18-gene transcriptomic proliferation signature ( r = 0.834), and both decreased significantly during treatment (P < 0.0001). An annotation-free pixel-wise Ki67 H-score showed weaker correlations and a similar but non-significant reduction ( r = 0.327-0.472; P = 0.15), highlighting differences between tumour-focused and whole-section image quantification. Digital pathology and spatial molecular measurements remained linked to their source images and annotated tissue regions, enabling exploration within their morphological and spatial context using bespoke interactive applications. POETIC-AI demonstrates how the structure, provenance, and tissue context of evolving multimodal clinical-trial data can be preserved within a connected research environment, supporting reproducible analyses and the laying the groundwork for future development of biologically interpretable computational biomarkers.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pathway analysis comparing the illumina and Affymetrix datasets as described in Supplementary Methods.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pathway analysis comparing the illumina and Affymetrix datasets as described in Supplementary Methods.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Immune cell deconvolution from molecular data. Relative proportions of immune cell subtypes are predicted from gene expression data using the Danaher method, and from methylation data using methylCIBERSORT. Differences between progressive and regressive groups are reported here.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Immune cell deconvolution from molecular data. Relative proportions of immune cell subtypes are predicted from gene expression data using the Danaher method, and from methylation data using methylCIBERSORT. Differences between progressive and regressive groups are reported here.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Markers used to define cell types in quantitative multiplex immunohistochemistry experiments.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Markers used to define cell types in quantitative multiplex immunohistochemistry experiments.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.